Veracyte
Veracyte, Inc., a leading genomic diagnostics company headquartered in the United States, is at the forefront of transforming patient care through innovative solutions. Founded in 2013, Veracyte has made significant strides in the field of molecular diagnostics, particularly in oncology and pulmonary diseases. The company’s core offerings include advanced genomic tests that provide critical insights for accurate disease diagnosis and management, setting them apart in a competitive market.
With a strong presence in the US and expanding operations globally, Veracyte has established itself as a trusted partner for healthcare providers. Notable achievements include the development of unique tests that enhance the diagnostic process, thereby improving patient outcomes. As a pioneer in the industry, Veracyte continues to lead the way in precision medicine, making significant contributions to the evolving landscape of genomic healthcare.
-14 vs industry average
Veracyte’s score of 26 is lower than 27% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Veracyte?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Veracyte yet.
Veracyte's reported carbon emissions
Veracyte, based in the US, is committed to climate action. While specific, recent emissions data in kg CO2e is not available, the company has established near-term targets as part of its commitment. Veracyte's climate initiatives are not currently cascaded from a parent organisation, indicating these commitments are directly from Veracyte, Inc. The company operates within the Healthcare Providers and Services, and Healthcare Technology sectors, highlighting its engagement with sustainability in the health industry. Further details on long-term targets or net-zero commitments are not specified.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Veracyte’s Climate Goals (2030 & 2050)
2 goals2030
42% reduction in Scope 1
Veracyte, Inc. commits to reduce absolute scope 1 and 2 GHG emissions 42.0% by 2030 from a 2024 base year
2030
25% reduction in scope 3 upstream
Veracyte, Inc. also commits to reduce absolute scope 3 GHG emissions from purchased goods and services, fuel- and energy-related activities,…
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Veracyte
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project